Navigation Links
Drug Company Halts Late-Stage Trial of Sickle-Cell Disease Drug

Drug manufacturer Icagen announced that it has ended its Phase III clinical trial of its sickle-cell treatment senicapoc, citing lack of effectiveness//, the Raleigh News & Observer reports.

Sickle-cell disease is a genetic blood disorder primarily affecting blacks, but can also be found Hispanics and people from the Middle East, Southeast Asia and the Mediterranean region.

Final testing in the 160-participant senicapoc study began in February 2005, and concerns about the treatment's effectiveness arose in August 2006 after the study's data monitoring committee suggested that senicapoc likely would benefit only a small number of people.

Icagen and Johnson & Johnson -- which paid $15 million to market and help develop the drug -- at that point decided to adjust the number of participants and treatment options being tested in the trial.

Recently, the committee said preliminary trial data show that senicapoc does not prevent chronic pain, one of the disease's most prominent complications. However, the drug consistently has been able to reduce the number of deformed blood cells associated with the disease. That effect "might make the drug suitable to reduce elevated blood pressure in the lungs of some sickle-cell patients and the stroke risk for pediatric sickle-cell patients," according to the News & Observer.

Currently, there is only one other treatment available for the disease. Richard Katz, Icagen's senior vice president of finance and corporate development, said that despite the findings, "it would be premature to say senicapoc is dead." He said the drug's future should be clearer in a few months.

Source-Kaiser Family Foundation/M
'"/>




Page: 1

Related medicine news :

1. Problems Of a Growing Company
2. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Elderly People Prefer The Company Of Pet Dogs
5. Ossur Acquires the U.S. Orthopaedics Company
6. Britain Approves Indian Company For Supplying Medicines
7. Drug Company Admits Knowledge Of Side Effects In Monkeys
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. Indian Training Company To Train Children In Dubai, Sharjah
10. GE Healthcare to Acquire Swedish Medical Company
11. Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX ... media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes ... use drop zones. Editors can select from a variety of flip book animations. In ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... is bringing their 100% all-natural lice removal service to ... 13 th Street was specifically chosen to make treatment convenient ... goal is to ease parents, stress and bring their lives back ... back to class without skipping a beat. The best part is ... whole family," Licenders President Adie Horowitz states. ...
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC announced ... recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 and ... same target on B cells as Rituxan and maintains ... but is also involved in tumor targeting, engagement of ... effect. The results of the study (abstract #95954) were ...
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
Breaking Medicine Technology: